Premium
Molecular analysis of PTEN and MXI1 in primary bladder carcinoma
Author(s) -
Wang David S.,
RiegerChrist Kimberly,
Latini Jerilyn M.,
Moinzadeh Ali,
Stoffel John,
Pezza John A.,
Saini Kulvinder,
Libertino John A.,
Summerhayes Ian C.
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20001115)88:4<620::aid-ijc16>3.0.co;2-z
Subject(s) - pten , loss of heterozygosity , cancer research , tumor suppressor gene , missense mutation , biology , point mutation , bladder cancer , carcinoma , locus (genetics) , urinary bladder , primary tumor , carcinogenesis , gene , mutation , pathology , cancer , genetics , medicine , allele , metastasis , pi3k/akt/mtor pathway , apoptosis
Loss of heterozygosity (LOH) on 10q is associated with late‐stage events in urothelial neoplastic progression. The tumor suppressor gene PTEN, which is mutated or homozygously deleted in numerous cancers, maps to a region of 10q within the reported region of minimal loss in bladder tumors. In two recent studies alterations in the PTEN gene occur at a low frequency in bladder tumors displaying 10q LOH. We have screened 35 late‐stage bladder tumors for mutations in PTEN and MXI1, both genes mapping to chromosome 10q. Using single‐strand conformation polymorphism analysis, we identified 6 tumors harboring mutations in PTEN and 2 additional tumors displaying homozygous deletion at this locus. No MXI1 mutations were identified within the same tumor panel. Of 16 bladder tumor cell lines analyzed, 2 showed homozygous deletion of PTEN and 3 harbored point mutations resulting in an amino acid change. Two cell lines harbored missense mutations in MXI1. We report a significantly higher frequency of PTEN alterations in bladder carcinoma (23%) than was previously recorded, with no accompanying mutations in the MXI1 gene. Int. J. Cancer 88:620–625, 2000. © 2000 Wiley‐Liss, Inc.